An Australian stem cell and regenerative medicine company

December 07, 2023

Approval to launch phase two trial of CYP-001 in Turkey

Following regulatory and ethics clearance to initiate a Phase 2 clinical trial for CYP-001 in patients with High-Risk acute Graft versus Host Disease at clinical sites in Turkey, Cynata plans to establish multiple clinical centers, commencing site initiation visits in the next 1-2 months. 

Read more here